MetLife, Inc. (MET)

On our desk, MET continues to screen as an intriguing value proposition. With a forward P/E sitting below the industry average at 7.97x and an A-level credit-backed balance sheet, the recent Q2 earnings beat reaffirms the buy case. Management's disciplined execution of the 'New Frontier' strategy—balancing capital-light fee businesses with spread businesses—gives us confidence heading into 2026. However, we remain cautious about macro headwinds, particularly fixed-income sensitivity to interest rate fluctuations.

From a quantitative perspective, MET's operational leverage is catching our attention. The deployment of AI at scale for claims processing and data density optimization is a structural tailwind worth tracking during due diligence. Furthermore, beating consensus on EPS by 5.6% while maintaining an adjusted ROE of 17% demonstrates efficient capital allocation. Keep an eye on expense-ratio targets beating expectations as a primary indicator of operational efficiency.

Watching the fixed-income allocation closely on our risk models. While MetLife's organic growth and diversified geographic exposure—including record results in Latin America—are impressive, the underlying reliance on favorable mortality trends in Group Benefits cannot be sustained indefinitely. Management explicitly noted these tailwinds will normalize over the back half of the year. Investors should factor in these normalization risks before sizing up positions.